# A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

> **NCT03872947** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Toray Industries, Inc** · enrollment: 138 (actual)

## Conditions studied

- Solid Tumor
- Colorectal Cancer
- Cholangiocarcinoma
- Bladder Cancer
- Ovarian Cancer
- Gastric Cancer
- Palpable Subcutaneous Malignant Lesions
- Renal Cell Carcinoma
- Melanoma
- Epithelial Ovarian Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer

## Interventions

- **BIOLOGICAL:** TRK-950
- **BIOLOGICAL:** TRK-950
- **BIOLOGICAL:** TRK-950
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin
- **DRUG:** 5-FU
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Ramucirumab
- **DRUG:** Paclitaxel
- **DRUG:** Nivolumab
- **DRUG:** Pembrolizumab
- **DRUG:** Imiquimod Cream
- **DRUG:** Bevacizumab
- **DRUG:** PLD

## Key facts

- **NCT ID:** NCT03872947
- **Lead sponsor:** Toray Industries, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-04-26
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03872947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03872947, "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03872947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*